Changiz Taghibiglou, PharmD/PhD
Primary tabs
JAD profile
Affiliation(s):
Dept. Pharmacology; College of Medicine; University of Saskatchewan
Areas of Interest:
Excitotoxicity-induced neuronal apoptosis in stroke and neurodegenerative diseases, Traumatic Brain Injury and Concussion, Neurobiology of Lipids, Lipid rafts and neuronal receptor signaling and trafficking, Brain insulin signaling, Designing bioactive short peptides
Biography & Research:
Changiz Taghibiglou, Pharm.D/Ph.D., is an Associate Professor of Pharmacology, at the College of Medicine, University of Saskatchewan (U of S), Canada. He obtained his Doctor of Pharmacy degree from Tabriz University of Medical Sciences, Tabriz-Iran. After several years of research and teaching in Iranian universities, he joined Dr. K. Adeli’s laboratory to do research on diabetic dyslipidemia at the Hospital for Sick Children, University of Toronto, and received his PhD from the Department of Laboratory Medicine & Pathobiology in 2001. He received both Canadian Institute for Health Research (CIHR) and Michael Smith Foundation for Health Research (MSFHR) post-doctoral fellowships (PDFs) and joined Dr. Yu Tian Wang’s research team at the Brain Research Centre, Dept. of Medicine, University of British Columbia in Vancouver Canada. Dr. Taghibiglou later worked as a research associate for Drs. Yu Tian Wang and Neil Cashman before joining U of S, as an Assistant Professor of Neuropharmcology in 2011.
Dr. Taghibiglou’s research in UBC resulted in publishing several high impact and highly cited peer-reviewed publications in journals Such as Nature Medicine, Neuron (with Dr. Graham Collingridge), EMBOJ, etc. His Nature Medicine published article connecting lipid transcription factor SREBP1 to GluN2B subunit of NMDA receptor and stroke was awarded the CIHR Brain Star Award in 2009. Dr. Taghibiglou’s research is focused on the role of SREBP1 and lipids in pathogenesis of brain insulin resistance, stroke, traumatic brain injury (TBI) and neurodegenerative diseases. He is also currently investigating potential connections between mTBI and neurodegenerative diseases.
